SEC Form 4
FORM 4
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *

NIVEN RALPH
(Last) (First) (Middle)

C/O AEROVATE THERAPEUTICS, INC.
930 WINTER STREET, SUITE M-500

## (Street)

| WALTHAM | MA | 02451 |
| :--- | :--- | :--- |
| (City) | (State) | (Zip) |

2. Issuer Name and Ticker or Trading Symbol
Aerovate Therapeutics, Inc. [ AVTE ]
3. Date of Earliest Transaction (Month/Day/Year) 11/07/2022
4. If Amendment, Date of Original Filed (Month/Day/Year)
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

| Director | 10\% Owner |
| :--- | :--- |
| Officer (give title <br> below) | Other (specify <br> below) |

CHIEF SCIENTIFIC OFFICER

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. <br> Transaction Code (Instr. 8) |  | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) |  |  | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | Code | v | Amount | (A) or <br> (D) | Price |  |  |  |
| Common Stock | 11/07/2022 |  | $\mathrm{M}^{(1)}$ |  | 650 | A | \$1.74 | 2,259 | D |  |
| Common Stock | 11/07/2022 |  | $M^{(1)}$ |  | 1,600 | A | \$2.14 | 3,859 | D |  |
| Common Stock | 11/07/2022 |  | $\mathrm{S}^{(1)}$ |  | 450 | D | \$17.091 ${ }^{(2)}$ | 3,409 | D |  |
| Common Stock | 11/07/2022 |  | $\mathrm{S}^{(1)}$ |  | 155 | D | \$18.023 ${ }^{(3)}$ | 3,254 | D |  |
| Common Stock | 11/07/2022 |  | $\mathrm{S}^{(1)}$ |  | 1,430 | D | \$19.823 ${ }^{(4)}$ | 1,824 | D |  |
| Common Stock | 11/07/2022 |  | $\mathrm{S}^{(1)}$ |  | 215 | D | \$20.293 ${ }^{(5)}$ | 1,609 | D |  |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. <br> Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any <br> (Month/Day/Year) | 4. <br> Trans Code 8) <br> Code | ction Instr. | 5. N of Deri Sec Acq (A) Disp of (D) (Ins and <br> (A) | mber <br> ative rities ired <br> sed <br> 3, 4 <br> ) <br> (D) | 6. Date Exerc Expiration D (Month/Day/ <br> Date <br> Exercisable | isable and te <br> ear) | 7. Title and Amount Securitie Underlyi Derivativ (Instr. 3 <br> Title | od <br> SSecurity <br> Amount <br> or <br> Number <br> of <br> Shares | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative <br> Securities <br> Beneficially <br> Owned <br> Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Stock <br> Option <br> (Right to <br> Buy) | \$1.74 | 11/07/2022 |  | $\mathrm{M}^{(1)}$ |  |  | 450 | (6) | 09/03/2030 | $\begin{aligned} & \text { Common } \\ & \text { Stock } \end{aligned}$ | 450 | \$0 | 22,308 | D |  |
| Stock <br> Option <br> (Right to <br> Buy) | \$1.74 | 11/07/2022 |  | $\mathrm{M}^{(1)}$ |  |  | 200 | (7) | 09/03/2030 | $\begin{aligned} & \text { Common } \\ & \text { Stock } \end{aligned}$ | 200 | \$0 | 13,688 | D |  |
| Stock <br> Option <br> (Right to <br> Buy) | \$2.14 | 11/07/2022 |  | $\mathrm{M}^{(1)}$ |  |  | 200 | (8) | 04/01/2031 | $\begin{aligned} & \text { Common } \\ & \text { Stock } \end{aligned}$ | 200 | \$0 | 15,494 | D |  |
|  | \$2.14 | 11/07/2022 |  | $\mathrm{M}^{(1)}$ |  |  | 650 | (9) | 04/01/2031 | $\begin{aligned} & \text { Common } \\ & \text { Stock } \end{aligned}$ | 650 | \$0 | 47,308 | D |  |
|  | \$2.14 | 11/07/2022 |  | $\mathrm{M}^{(1)}$ |  |  | 750 | (10) | 04/01/2031 | $\begin{aligned} & \text { Common } \\ & \text { Stock } \end{aligned}$ | 750 | \$0 | 56,732 | D |  |

## Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022.
2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $\$ 16.67$ to $\$ 17.41$, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $\$ 17.70$ to $\$ 18.62$, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $\$ 19.15$ to $\$ 20.14$, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
5. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $\$ 20.21$ to $\$ 20.51$, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
6. A total of 24,108 shares subject to an employee stock option were granted on September 4,2020 , with $25 \%$ of this option vested on August 1 , 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
7. A total of 14,488 shares subject to an employee stock option were granted on September 4 , 2020, with $25 \%$ of this option vested on June 1 , 2021 , and the remainder vesting in 36 substantially equal monthly

# 10. A total of 59,732 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4 , 2021. 

| /s/ George A. Eldridge, | $\underline{11 / 09 / 2022}$ |
| :--- | :--- |
| Attorney-in-Fact Signature of Reporting Person | Date |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v)
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. $78 \mathrm{ff}(\mathrm{a})$.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

